MedTrace Logo

Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy

NCT06647602 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2026-02-10

No results posted yet for this study

Summary

This study will be a multicentre prospective cohort study on TH-substitution after thyroid hormone withdrawal preceding radioiodine treatment.

Conditions

  • Differentiated Thyroid Cancer
  • Thyroid Cancer
  • Levothyroxine
  • Liothyronine
  • Thyroid Hormones

Interventions

DRUG

Euthyrox (levothyroxine)

Euthyrox (levothyroxine sodium tablets; L-T4) is a thyromimetic synthetic drug identical to T4. Patients will recieve levothyroxine (euthyrox) in a dose of 2 μg × kg body weight / day.

DRUG

Cytomel (liothyronine)

Cytomel (liothyronine sodium tablets; L-T3) is a thyromimetic synthetic drug identical to T3. The patients in this cohort recieve L-T4+L-T3 combination therapy. The L-T4 dose will be 2 μg × kg body weight / day, equal to the dose in the other interventional arm. L-T3 will be added twice daily from the first day of combination treatment, in dosages gradually decreasing from 25 ug 2/day to 5 ug 2/day over a time span of 3 weeks after which L-T3 is stopped.

Sponsors & Collaborators

  • Radboud University Medical Center

    collaborator OTHER

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • Wouter Zandee, MD/PhD · University Medical Center Groningen

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2028-03-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06647602 on ClinicalTrials.gov